Cardinal Capital Management boosted its position in Sanofi (NYSE:SNY) by 20.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 53,544 shares of the company’s stock after buying an additional 9,087 shares during the period. Cardinal Capital Management’s holdings in Sanofi were worth $2,565,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the company. Janney Montgomery Scott LLC increased its stake in shares of Sanofi by 6.6% in the second quarter. Janney Montgomery Scott LLC now owns 114,388 shares of the company’s stock worth $5,480,000 after buying an additional 7,051 shares during the period. Harbour Capital Advisors LLC increased its stake in shares of Sanofi by 4,691.0% in the second quarter. Harbour Capital Advisors LLC now owns 119,775 shares of the company’s stock worth $2,500,000 after buying an additional 117,275 shares during the period. Park Avenue Securities LLC purchased a new stake in shares of Sanofi during the second quarter worth about $245,000. Cutler Capital Management LLC increased its stake in shares of Sanofi by 0.8% in the second quarter. Cutler Capital Management LLC now owns 159,524 shares of the company’s stock worth $7,643,000 after buying an additional 1,324 shares during the period. Finally, Boston Advisors LLC purchased a new stake in shares of Sanofi during the second quarter worth about $638,000. 9.96% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Sanofi (SNY) traded up 0.30% during midday trading on Friday, hitting $47.55. 717,957 shares of the stock were exchanged. The firm has a 50-day moving average price of $47.99 and a 200 day moving average price of $46.11. The firm has a market cap of $119.42 billion, a PE ratio of 11.23 and a beta of 0.88. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.24.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi’s quarterly revenue was down 2.3% compared to the same quarter last year. Analysts predict that Sanofi will post $3.26 earnings per share for the current fiscal year.
Several equities analysts have issued reports on the stock. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price objective (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Argus increased their price objective on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a report on Friday, June 2nd. Finally, Berenberg Bank downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $63.75.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.